Annexin Pharmaceuticals AB (ANNX) — Cash Flow-to-Debt Ratio
Annexin Pharmaceuticals AB (ANNX) has a Cash Flow-to-Debt Ratio of -1.86x as of March 2026, meaning its operating cash flow of Skr-10.33 Million could theoretically repay -2% of its total liabilities (Skr5.56 Million) in one year. Explore ANNX operating cash flow to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Annexin Pharmaceuticals AB Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Annexin Pharmaceuticals AB across 11 annual periods. Also explore total assets of Annexin Pharmaceuticals AB for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Annexin Pharmaceuticals AB (2015–2025)
Year-by-year debt coverage analysis for Annexin Pharmaceuticals AB. For market capitalisation and broader financial context, see Annexin Pharmaceuticals AB stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -7.07x | Skr-36.92 Million | Skr5.22 Million | ▲ +25.1% |
| 2024 | -9.44x | Skr-50.23 Million | Skr5.32 Million | ▼ -72.8% |
| 2023 | -5.46x | Skr-43.40 Million | Skr7.95 Million | ▲ +13.4% |
| 2022 | -6.31x | Skr-41.16 Million | Skr6.53 Million | ▲ +15.1% |
| 2021 | -7.43x | Skr-45.02 Million | Skr6.06 Million | ▲ +14.3% |
| 2020 | -8.67x | Skr-39.20 Million | Skr4.52 Million | ▼ -53.3% |
| 2019 | -5.66x | Skr-25.73 Million | Skr4.55 Million | ▼ -22.8% |
| 2018 | -4.61x | Skr-28.50 Million | Skr6.19 Million | ▲ +24.5% |
| 2017 | -6.10x | Skr-39.08 Million | Skr6.41 Million | ▼ -383.3% |
| 2016 | -1.26x | Skr-9.95 Million | Skr7.88 Million | ▲ +17.4% |
| 2015 | -1.53x | Skr-5.01 Million | Skr3.28 Million | — |